Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Day One Biopharmaceuticals, Inc. develops targeted oncology therapies for pediatric and adult cancers. Its core product, tovorafenib, is a brain-penetrant RAF kinase inhibitor targeting RAF-driven tumors, including pediatric low-grade glioma. The company focuses on innovative, first- or best-in-class medicines, leveraging clinical development, strategic partnerships, and licensing to address high unmet medical needs across global markets. Its pipeline includes antibody-drug conjugates and kinase inhibitors for high-impact cancers.
This description was generated via AI from an annual report. Updated about 1 year ago.